Relay Therapeutics is committed to discovering and developing medicines that will make a transformative difference for patients by building the first dedicated drug discovery pipeline centered on protein motion. Bringing together the latest scientific advances in structural biology, biophysics, computation, chemistry and biology, Relay's drug discovery engine illuminates the full mobility of a protein and the ways in which protein motion regulates function. By applying this approach as an integrated team focused on disease-causing targets, Relay aims to develop breakthrough medicines for patients in need. The company's initial programs are focused on developing therapeutics in oncology. Headquartered in Cambridge, Massachusetts, Relay Therapeutics is a private company launched in 2016 with $57 million in Series A financing from Third Rock Ventures and an affiliate of D. E. Shaw Research.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
09/14/16	$57,000,000	Series A	D.E. Shaw Ventures Third Rock Ventures	undisclosed
12/14/17	$63,000,000	Series B	Alexandria Venture Investments BVF Partners Casdin Capital EcoR1 Capital Section 32 Third Rock Ventures	undisclosed
12/27/18	$400,000,000	Series C	Alexandria Venture Investments BVF Partners Casdin Capital EcoR1 Capital Foresite Capital Perceptive Advisors SoftBank Vision Fund Tavistock Group	undisclosed